A miracle happened for the first time in the history of cancer. For the first time in history, the new monoclonal antibody drug Dostarlimab cured every Colorectal Cancer patient during “experimental immunotherapy treatment”. Finally, Cancer Researchers are able to find cures for cancer.
According to the New York Times, a new drug clinical trial was conducted in the Memorial Sloan Kettering Cancer Centre in New York. This clinical trial showed a miracle effect in the 18 patients with colorectal cancer who took the new monoclonal drug Dostarlimab for six months in a limited clinical trial means. In those patients, the disease has vanished. Medical Oncologist and study co-author of the paper, Dr Luis Diaz, revealed that this trial was largely positive for the cure of colorectal cancer patients in the clinical trial.
Doctors were stunned when no malignancy was detectable during physical examination, endoscopy, positron emission tomography, PET scans, or MRI scans. According to the news in the New York Times, these patients received a treatment of chemotherapy, radiation and invasive surgery before the clinical trial experiments. They expected to have to go through the surgery as the next step in the research. Experts were astonished by the trial positive outcome.
Doctors said, the patient took a new drug every three weeks for six months they were observed after completion of the clinical trial they all were in some stage of the disease, and cancer had not spread to other organs. The patient did not receive any chemotherapy or surgery.
What Is Colorectal Cancer
Colorectal cancer is the second most common reason for death in the U.S. The American Cancer Society estimated that 44,850 death will occur in 2022 due to rectal cancer.
Colorectal Cancer is also called colon cancer and it is also known as Bowel Cancer depending upon where they start. It begins with the large intestine or rectum. It is a disease in which cells of the colon or rectal grow out of control. The colon is the large intestine or large bowel of our body and the rectum is the passway that connects the colon to the anus.
Sometimes abnormal growth occurred in the colon or rectum which is called Polyps. Over time these polyps may turn into cancer. Patients can get these polyps by screening tests so these can be removed before turning into cancer.
What Is Dostarlimab Drug & its Significant
Dostarlimab is a monoclonal antibody (Synthetic antibody). This monoclonal antibody has a strong ability to build strong immunity against a pathogen. Dostarlimab is administered to the patient every three weeks for six months.
Dostarlimab drugs is not a new drug, it has been used earlier to treat endometrial cancer. This drug is also known as a “Checkpoint inhibitor”.It means that instead of killing cancers it allows the immune system of patients to kill the cells on its own, thus it is considered immunotherapy. This drug exhibits some kind of adverse reaction in approx 20 % of patients. Approx 60% of patients suffered from severe complications including muscle weakness. But no negative effects were seen in the patients involved in the clinical trial of Dostarlimab.
Frequently Asked Question
Que: How does Dostarlimab work?
Ans: When we provide immunotherapy to the patient then it works by unlocking the immune system to fight cancer.
Que: What is the incidence of rectal cancer in India?
Ans: The incidence rate of rectal cancer in India is range from 3.9 to 4.4 per 100,000.
Que: What is the minimum period of the clinical trial.
Ans: There is no time period for the clinical trial. It may take 10-15 years or more to complete all three phases.
Que: What are the risks of the clinical trials?
Ans: The risk of the clinical trial may be unpleasant, serious or even life-threatening experimental treatment.
Que: Why clinical trials are important?
Ans: Clinical trials are important to discover new drugs for the treatment of diseases, and new ways to detect, diagnose, and are also helpful to reduce the chances of developing the disease.
The clinical study of Dostarlimab showed a miraculous effect in colorectal cancer patients. With its positive results, the world may soon be getting rid of this disease. In a clinical trial first time, a drug has shown its 100 % suppression of cancer in patients at Memorial Sloan Kettering Cancer Center in Manhattan, U.S.
Disclaimer: All the content of this article is for information purposes only.